ABSTRACT
During the course of the disease, patients with myeloma experience a number of complications that are secondary to the widespread immunologic, haematologic, and hormonal/cytokine abnormalities seen in plasma cell dyscrasias. These include infections, hypercalcaemia, anaemia, pain, and fractures. Adequate prophylaxis and therapy of these complications is essential to improve patients’ quality of life, ensure adequate delivery of cytoreductive therapy, and, sometimes, to prevent fatal consequences.
